Foot Drop and Numb Hands After Fast Weight Loss: GLP-1 Drugs and Pinched Nerves

Two men taking tirzepatide for weight loss developed the same problem. Over 24 to 72 hours, each developed foot drop, a weakness that makes it hard to lift the front of the foot. One, a 55-year-old, had lost 50 pounds in five months; the other, a 71-year-old, had lost 30 pounds in three. Doctors at the Touro College of Osteopathic Medicine, who described them in Case Reports in Neurology in 2026, traced both cases to the peroneal nerve, which runs just under the skin around the outside of the knee, and to a habit the men shared: crossing their legs for long stretches.

The treatment was simple. They stopped crossing their legs, did physical therapy, and one wore an ankle brace. The foot drop cleared over three to four months.

These are not the only reports. A Medical University of South Carolina team described two other tirzepatide users who developed foot drop in both legs six to eight months into treatment, and surgeons at the University of Arizona College of Medicine-Phoenix reported two patients without diabetes who developed foot drop after losing 14% and 18% of their body weight over three to six months on semaglutide and tirzepatide. Case reports like these show that something can happen. They cannot say how often it does.

Doctors have a name for this: slimmer's paralysis, or slimmer's palsy. In 1984 the neurologist K.A. Sotaniemi described 10 people who developed nerve problems while dieting. Nine had weakness from the peroneal nerve on one side, and one had a widespread nerve disorder blamed on low thiamine (vitamin B1). Sotaniemi argued that metabolic changes from dieting, more than pressure, were the cause.

A larger Madrid series in 2000 pointed back toward pressure. Electrodiagnostic tests in 30 people with sudden peroneal palsy after a weight-loss diet showed the nerve signal was blocked right at the head of the fibula, the bony bump below the outside of the knee, and 29 of them recovered within three weeks to three months. Three had a wider nerve disorder that testing tied to an inherited condition that makes nerves unusually sensitive to pressure.

The working idea in recent reports is that fat around the fibular head cushions the peroneal nerve, and losing that padding quickly leaves the nerve pressed between bone and whatever the leg rests on. The Arizona surgeons call it "a predictable and treatable complication of rapid weight loss." They note it has been described with other causes of rapid weight loss, including anorexia, cancer, and recovery from biliary surgery.

The newest study looks at the arms. Researchers at Washington University School of Medicine in St. Louis reported in HAND on October 26, 2026 a study of TriNetX health records for adults who had bariatric surgery between January 2015 and February 2026, comparing 11,158 who also took a GLP-1 drug with 11,158 matched patients who had surgery alone.

Over a median of one year, the GLP-1 group had 63% more new diagnoses of carpal tunnel syndrome, which pinches the median nerve at the wrist (risk ratio 1.63), and about twice as many diagnoses of cubital tunnel syndrome, which pinches the ulnar nerve at the elbow (2.10). They were also more likely to have nerve-conduction testing (1.43). Carpal tunnel release surgery was not significantly more common (1.54, with a confidence interval of 0.77 to 3.09).

The groups were not identical before treatment. The GLP-1 patients were younger (50.6 vs 53.5 years) and had a lower average BMI (39.9 vs 42.6). The authors read the pattern of more diagnoses without more surgery as greater susceptibility to nerve compression, and they say the mechanism and the right monitoring still need study.

Studies of people with type 2 diabetes point the other way. Diabetes itself raises carpal tunnel risk, and in several large records studies, GLP-1 users were diagnosed less often.

A Temple University team compared 555,267 matched pairs of adults with type 2 diabetes in TriNetX and found carpal tunnel syndrome in 4.8% of GLP-1 users versus 5.5% of nonusers (risk ratio 0.89). Yet GLP-1 users were more likely to have carpal tunnel release surgery (1.14). A Mayo Clinic Alix School of Medicine study using a national claims database found GLP-1 therapy linked to about half the odds of a carpal tunnel diagnosis within two years (odds ratio 0.49), but, among people who were diagnosed, higher odds of surgery (1.23). In an analysis of U.S. TriNetX records by a Chi-Mei Medical Center team in Taiwan, covering adults with overweight or obesity, tirzepatide users had a lower risk of carpal tunnel syndrome than users of other GLP-1 drugs (hazard ratio 0.82) and of orlistat or phentermine (0.75).

Not every comparison favors GLP-1 drugs. A 2024 study of 65,464 matched pairs with type 2 diabetes found SGLT2 inhibitor users had slightly lower carpal tunnel risk than GLP-1 users (hazard ratio 0.93).

The studies differ in who they followed. The diabetes studies looked at people whose blood sugar and metabolic health may improve on the drug, while the Washington University study looked at people already losing a large amount of weight after surgery and adding a GLP-1 on top. All of these are observational record studies, and none can show that the drug caused the difference.

Some GLP-1 users report a different kind of nerve symptom. Dysesthesia, an umbrella term the Wegovy label uses for burning, tingling, pins-and-needles, or skin that hurts to touch, became common at the highest semaglutide dose. In the trials behind Wegovy HD, it occurred in 22% of people on 7.2 mg, 6% on 2.4 mg, and almost no one on placebo, and the label says it rose with dose and drug levels in the blood. The Zepbound label reports it in 0.4% or fewer of tirzepatide users.

Dysesthesia is counted in trials as a drug side effect, compared with placebo. A compressed nerve is a different problem and tends to cause symptoms in one area: the thumb, index, and middle fingers with carpal tunnel, the ring and little fingers with cubital tunnel, or weakness lifting one foot with peroneal palsy. Our article on the dysesthesia signal covers the trial data for semaglutide and retatrutide.

Rapid weight loss can also cause nerve problems through diet rather than pressure. In a Mayo Clinic study published in Neurology in 2004, 71 of 435 people (16%) developed peripheral neuropathy after bariatric surgery, compared with 4 of 126 (3%) after gallbladder surgery, and the authors named malnutrition as possibly the most important risk factor. Sotaniemi's 1984 series included a dieter whose nerve damage was blamed on thiamine deficiency.

Medications matter too. In the Diabetes Prevention Program Outcomes Study, low vitamin B12 was more common with metformin than placebo at five years (4.3% vs 2.3%), and the authors suggested routine B12 testing for people taking metformin. Eating much less, as these drugs cause, makes it worth asking whether nutrition is keeping up; our guide to protein and resistance training on GLP-1s covers the eating side.

Sudden weakness lifting a foot, toes that catch or drag, or numbness or weakness that stays in specific fingers are reasons to see a clinician rather than wait. In the published foot-drop cases, recovery took weeks to months, and the Arizona surgeons warn that some cases need treatment before nerve damage becomes permanent.

Useful questions to bring:

• Is my weight coming off faster than expected, and should my dose increase more slowly? Our dosing schedules guide explains how labels pace the climb.
• Could habits like crossing my legs, leaning on my elbows, or sleeping with bent wrists be pressing on a nerve?
• Should I have vitamin B12 or other nutrient levels checked, especially if I take metformin or have had bariatric surgery?
• Do these symptoms need a nerve-conduction study, and who should I see?
• Is this more likely a pinched nerve, diabetic neuropathy, or the skin-sensation side effect listed on my drug's label?

If you are combining a GLP-1 drug with bariatric surgery, our comparison of GLP-1s and surgery covers how the two approaches differ.